Author Login

Correspondence to Author: Qingquan Luo, 

Department of Thoracic Surgery, The People’s Hospital of Dongyang City, China.

Introduction:

In China and around the world, lung cancer is the most common type of cancer to be diagnosed and the primary cause of cancer-related fatalities [1]. In 2012, there were an estimated 1.8 million new instances of lung cancer, making up roughly 13% of all cancer diagnoses [2]. Over 80% of cases of lung cancer are not minor ones.NSCLC (small cell lung cancer) [3]. While patients with localized NSCLC have a 5-year survival rate of over 50%, 57% of patients had progressed or metastatic NSCLC at diagnosis, which has a 5-year survival rate of only 5% [4]. A platinum-based doublet comprising third-generation cytotoxic drugs (such as carboplatin plus paclitaxel or cisplatin plus gemcitabine) is the recommended first-line treatment for advanced non-small cell lung cancer (NSCLC) in the absence of targetable genetic abnormalities [5,6]. Numerous individual chemotherapy regimens, such as those including gefitinib, erlotinib, pemetrexed, and docetaxel, have therapy of advanced non-small cell lung cancer (2012) [9, 10]. In patients with advanced non-small cell lung cancer (NSCLC), a phase III trial showed that nabpaclitaxel plus carboplatin considerably increased overall response rates when compared to traditional, solvent-based paclitaxel plus carboplatin [11]. More and more data have suggested that nab-paclitaxel, either alone or in conjunction with gemcitabine as a chemotherapeutic reagent, can be employed as the second-line treatment for gastric cancer [14] or pancreatic cancer [12, 13] that increases patient survival rates. Nevertheless, there is currently insufficient data to determine if nab-paclitaxel is a useful second-line chemotherapy treatment for patients with advanced nonsmall cell lung cancer. Consequently, we assessed the safety and effectiveness of nab-paclitaxel as a single reagent as a second-line therapy for patients who have progressed in this phase II clinical trial, which is randomized and placebocontrolled, in China.

MATERIALS AND PROCEDURES:   The current study’s protocols were all carried out in compliance with the Declaration of Helsinki and Good Clinical Guidelines for Practice. The People’s Hospital in Dongyang City’s ethics committees examined and authorized every procedure and treatment. Each patient who took part signed the consent forms.Participants in the current study were 92 eligible patients with advanced non-small cell lung cancer (NSCLC) who were seen at the People’s Hospital of Dongyang city in Dongyang, Zhejiang province, China, between October 2011 and October 2014. Individuals suffering from Two treatment groups, one with nab-paclitaxel (46 patients) and the other with placebocontrolled (46 patients), were randomly stratified (in a 1:1 ratio) for advanced NSCLC. Participants in the study had to meet certain criteria in order to be considered: they had to be between the ages of 18 and 75, have an advanced nonsmall cell lung cancer (NSCLC) with a performance status (PS) between 0 and 3, have received first-line platinum-based chemotherapy but the disease was still progressing, have a minimum life expectancy of three months, and have adequate hepatic, renal, or bone marrow functions.
The effectiveness and safety of nab-paclitaxel as secondline chemotherapy for Chinese patients with advanced non-small cell lung cancer (NSCLC) following platinumbased chemotherapy are being assessed in this open-label, placebo-controlled, randomized phase II clinical research. failure of first-line chemotherapy. Two weeks before to the study, chest and abdominal computed tomography scans were taken. For patients to be assessed for a response, they had to have at least one detectable lesion.
In order to administer medication, patients in the nabpaclitaxel group received 150 mg/m2 intravenously on days 1, 8, and 15 of a 4-week cycle. Patients should be treated for at least two cycles, with a maximum of six cycles, until they are unable to handle the adverse events (AEs) or request to stop the treatment.

Citation:

Qingquan Luo. Department of Thoracic Surgery, The People’s Hospital of Dongyang City, China. The Clinical Lung Cancer 2024.